Pitavastatin Reduces Major Atherosclerotic Cardiovascular Events in Adults with HIV
Initiation of pitavastatin in adults aged 40 to 75 living with HIV treated with highly active antiretroviral therapy (HAART) with low-to-moderate 10-year atherosclerotic cardiovascular disease (ASCVD) risk decreases the incidence of major cardiovascular events (MACE).
Authors
- Brock Cardon (ORCID: https://orcid.org/0000-0001-7138-5102)
- Kathryn K. Garner
- Chris Colvin
Institutions
- Mike O'Callaghan Federal Medical Center (US)
Publication Details
- Journal
- The Journal of the American Board of Family Medicine
- Published
- 2025-05-01
- DOI
- https://doi.org/10.3122/jabfm.2025.250014r0
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00